- Home
- GMED vs QGEN Comparison
GMED vs QGEN Comparison
Compare GMED & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMED
- QGEN
- Stock Information
- Founded
- GMED 2003
- QGEN 1986
- Country
- GMED United States
- QGEN Netherlands
- Employees
- GMED N/A
- QGEN N/A
- Industry
- GMED Medical/Dental Instruments
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GMED Health Care
- QGEN Health Care
- Exchange
- GMED Nasdaq
- QGEN Nasdaq
- Market Cap
- GMED 8.1B
- QGEN 9.1B
- IPO Year
- GMED 2012
- QGEN 1996
- Fundamental
- Price
- GMED $59.51
- QGEN $48.47
- Analyst Decision
- GMED Buy
- QGEN Buy
- Analyst Count
- GMED 13
- QGEN 9
- Target Price
- GMED $94.30
- QGEN $50.79
- AVG Volume (30 Days)
- GMED 1.1M
- QGEN 1.3M
- Earning Date
- GMED 08-05-2025
- QGEN 07-30-2025
- Dividend Yield
- GMED N/A
- QGEN 3.13%
- EPS Growth
- GMED 145.70
- QGEN N/A
- EPS
- GMED 1.34
- QGEN 0.42
- Revenue
- GMED $2,510,810,000.00
- QGEN $2,002,874,000.00
- Revenue This Year
- GMED $15.47
- QGEN $6.36
- Revenue Next Year
- GMED $8.97
- QGEN $6.18
- P/E Ratio
- GMED $45.45
- QGEN $114.65
- Revenue Growth
- GMED 32.26
- QGEN 3.31
- 52 Week Low
- GMED $54.48
- QGEN $37.63
- 52 Week High
- GMED $94.93
- QGEN $48.82
- Technical
- Relative Strength Index (RSI)
- GMED 47.52
- QGEN 70.56
- Support Level
- GMED $57.79
- QGEN $47.65
- Resistance Level
- GMED $61.29
- QGEN $48.82
- Average True Range (ATR)
- GMED 1.28
- QGEN 0.71
- MACD
- GMED 0.43
- QGEN 0.01
- Stochastic Oscillator
- GMED 60.51
- QGEN 87.63
About GMED Globus Medical Inc.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).